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Fungal infections caused by various fungal species have become a leading
cause of morbidity and mortality in the last decades. Although not recog-
nized as such for a long period of time, mainly because of the traditional view
that bacteria, viruses or parasites are the main human pathogens, there is
increasing awareness that fungal infections cause as heavy a burden on
human health as these other organisms [1]. In the Western societies, the high
burden of fungal infections is especially true for the severely ill patients,
both immunocompetent and immunocompromised, who have an increased
risk of nosocomial fungal infection. In contrast, in developing countries a
large array of fungal infections affect both immunocompromised (e.g. HIV-
infected) and otherwise healthy individuals [1]. Despite the discovery of
novel and more potent antifungal drugs against the major fungal pathogens
(Candida, Aspergillus, and Cryptococcus spp.), the mortality due to fungi
remains high, in the range from 30 to 50%, and it is believed that adjunctive
immunotherapy is the only approach that could improve this grim outcome
[2].
In order to be able to propose innovative new approaches for adjunctive
immunotherapy of fungal infections, a very solid knowledge on both the
pathogens and the host defense mechanisms against these organisms is
needed. The last years have witnessed a spectacular increase in our un-
derstanding of fungal pathogens and infections, and in this issue of Current
Opinion in Microbiology an overview of some of the most important of these
advances are presented.
In the first review of this series, Gow and Hube present an overview of the
current knowledge of the importance of the cell wall of Candida albicans
during commensalism and infection, a crucial step in understanding the host
defense against this most important human fungal pathogen. Firstly, the
authors review the cellular and molecular mechanisms that Candida employs
for the various stages of invasion: adhesion, invasion, and endothelial
damage, and the molecular changes during yeast-hyphal transformation
underpinning these processes. Secondly, the authors describe the important
knowledge obtained in the last decades on understanding recognition of
Candida by the innate immune system, the first and main line of immuno-
logical defense against the pathogens. The crucial role played by polysac-
charide structures of the cell wall (e.g. mannans, b-glucans or chitin) that are
recognized by pattern-recognition receptors is explained. Furthermore, they
discuss the interplay between C. albicans and epithelial cells, neutrophils and
macrophages/Th17 cells at the level of the mucosa during colonization and
infection. The authors conclude that the transition of C. albicans from
commensalism to invasive growth is a shift in the dynamic equilibrium
between host and pathogen associated factors, for which the fungus has
evolved mechanisms to counter the effects of the sentinel activity of
Available online at www.sciencedirect.com
Open access under CC BY license.www.sciencedirect.com Current Opinion in Microbiology 2012, 15:403–405
404 Host–microbe interactions: Fungimucosal immunity mechanisms. Understanding this pro-
cess could provide new targets for therapy.
An important subsequent step is the assessment of the
importance of these mechanisms in vivo. In this respect,
animal models of fungal infections play a crucial role,
on the one hand by mimicking the infection in the
patients, and on the other hand by allowing the study of
genetic or immunologic depletion of certain com-
ponents of the antifungal defense mechanisms. Steele
and Wormley present an overview of the role played by
animal models of fungal infections in understanding the
crucial steps necessary for an effective fungal elimin-
ation: the recognition by pattern recognition receptors
such as Toll-like receptors and C-type lectin receptors,
the role of polarization of cellular immune responses
towards Th1 or Th17, and the role of antibody-
mediated mechanisms of anti-fungal host defense.
They conclude that animal models of fungal pathogen-
esis have provided great insight into what occurs fol-
lowing the interaction of fungi with various innate and
adaptive immune cells.
Not only experimental animal models can help us in
understanding host defence against fungi, but also the
‘experiments of nature’ encountered in patients with
primary immunodeficiencies and an increased suscepti-
bility to fungal infections. In the review by Lilic in this
number of Current Opinion in Microbiology, we are pre-
sented with a systematic description of the important
defects in immunological mechanisms leading to recur-
rent and/or severe fungal infections. Recent work has
demonstrated the pivotal role of Th17 responses for the
mucosal antifungal defects, and genetic defects in genes
such as STAT1, STAT3, IL-17F , IL-17R, dectin-1, CARD9
or AIRE have all been associated with mucosal fungal
infections in the various variants of chronic mucocuta-
neous candidiasis syndromes described in the literature.
In addition, classical immunodeficiencies such as severe
combined immunodeficiency, CD4 lymphopenia or
chronic granulomatous disease are associated with
systemic fungal infections. The discovery of the mech-
anisms defective in these patients has proven crucial for
understanding the underlying pathways mediating host
defence in common infections with fungi, and for design-
ing effective vaccination or immunotherapy.
The step towards immunotherapy of fungal infections is
proposed in the next two reviews in the series. In the first
of these reviews, Cassone and Casadevall discuss the
progress and the future perspectives on the development
of vaccines against the major fungal pathogens. The
authors contemplate the chain of events that have pre-
cipitated the progress in the research for fungal vaccines
in the last years, including the medical plight of millions
of patients suffering from conditions such as recurrent
vulvovaginal candidiasis (RVVC, currently a major targetCurrent Opinion in Microbiology 2012, 15:403–405 for vaccine development) or systemic fungal infections in
the immunocompromised host, to the dedication of sev-
eral pioneering groups of investigators in the field. The
authors define the groups of patients most at need for
vaccination, and discuss the critical role played by the
combination of a proper antigenic component and a care-
fully tailored adjuvant for the efficiency of a vaccine.
Indeed, the recent knowledge gained in the role played
by humoral or cellular (Th1/Th17) immunity in the
protection against fungi gives the hope for vaccine strat-
egies adjusted to each patient group, and each of these
immune mechanisms are employed by the two vaccines
currently in phase I trials for RVVC.
Next to vaccines, immunotherapeutic approaches in the
already-ill patient should also be considered. Armstrong-
James and Harrison discuss in their review the novel
immunotherapeutic approaches employed in patients
with fungal diseases, therapies that aim to boost or aid
the host defense of the host. The authors discuss the
promising prospects of using recombinant cytokines such
as interferon-g for the treatment of systemic fungal infec-
tions, and the potential role of antibody-based immu-
notherapy. These already-tested approaches are
complemented in the vision of the authors by the possi-
bilities of employing in the future additional forms of
immunotherapy such as cell-based therapies using adop-
tive transfer of T-cells, DCs or neutrophils, while other
humoral approaches such as recombinant pentraxins are
also further in the pipeline. Gene therapy for severe
conditions such as chronic granulomatous disease is also
contemplated, and the authors conclude that all these
approaches hold great promise for the future of treatment
of fungal diseases.
While the progress towards understanding the host
defense mechanisms against fungi is undeniable, and
several of the target therapies have been or are currently
tested, one should not be complacent and cease exploring
new paths towards understanding host defense, leading to
novel drug discovery. In the last review of this series,
Tierney and colleagues present one of the most innova-
tive approaches to understand host defense against fungi
that is hoped to represent the next step in understanding
the interaction between the host and the pathogens. The
authors present the state-of-the-art systems biology
approaches that are beginning to be employed in the
study of fungal–host interaction, including transcrip-
tomics-based and functional genomics approaches (both
at the level of the host and fungus), genome dynamics of
the fungal pathogen, and infection modeling. The authors
are confident that systems biology holds the promise of
helping us to obtain holistic views on the extent of host–
fungal interaction, and to generate predictions of host–
microbe behavior and disease outcome. Combining math-
ematical modeling and functional genomics is proposed as
an approach to decipher the infectious processes andwww.sciencedirect.com
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infections.
In conclusion, the reviews of these series highlight on
the one hand the state-of-the-art research in under-
standing the interaction between the pathogenic fungi
and the host, and on the other hand the promising new
avenues towards an effective adjuvant immunotherapy
in fungal infections. As the field progresses, it is time to
be optimistic that in the not very distant future novel
therapeutic strategies aimed at disrupting fungal survi-
val mechanisms and augmenting the host defenses willwww.sciencedirect.com be designed and successfully deployed in patients with
fungal infections.
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